C. Denkert

发表

CD24 expression is a new prognostic marker in breast cancer.

C. Pilarsky, G. Kristiansen, K. Winzer, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients

I. Petersen, G. Kristiansen, K. Schlüns, 2003, British Journal of Cancer.

CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival.

C. Pilarsky, G. Kristiansen, K. Schlüns, 2002, The American journal of pathology.

Cytoplasmic CD24 Expression in Colorectal Cancer Independently Correlates with Shortened Patient Survival

W. Weichert, G. Kristiansen, J. Bellach, 2005, Clinical Cancer Research.

An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients

Z. Szallasi, C. Denkert, A. Eklund, 2010, Breast Cancer Research and Treatment.

CognitionMaster: an object-based image analysis framework

Masaru Ishii, Daniel Heim, Peter Hufnagl, 2013, Diagnostic Pathology.

Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group

Andrew H. Beck, Jacqueline A. Hall, Sarah N. Dudgeon, 2020, npj Breast Cancer.

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

T. Nielsen, E. Thompson, C. Sotiriou, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Metabolomics of human breast cancer: new approaches for tumor typing and biomarker discovery

Scarlet F. Brockmöller, O. Fiehn, C. Denkert, 2012, Genome Medicine.

Towards computational fluorescence microscopy: Machine learning-based integrated prediction of morphological and molecular tumor profiles pdf

Masaru Ishii, Alexander Binder, Klaus-Robert Müller, 2018, ArXiv.

Classical pathology and mutational load of breast cancer – integration of two worlds

W. Weichert, A. Stenzinger, C. Denkert, 2015, The journal of pathology. Clinical research.

Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.

P. Fasching, A. Schneeweiss, C. Denkert, 2018, The Lancet. Oncology.

Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.

T. Nielsen, S. Loi, C. Denkert, 2017, Seminars in cancer biology.

mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours.

W. Weichert, A. Stenzinger, C. Denkert, 2011, Endocrine-related cancer.

Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression.

Matej Oresic, Oliver Fiehn, Carsten Denkert, 2011, Cancer research.

Applying in-silico retention index and mass spectra matching for identification of unknown metabolites in accurate mass GC-TOF mass spectrometry.

Oliver Fiehn, Tobias Kind, Carsten Denkert, 2011, Analytical chemistry.

Integrated Systems and Technologies Metabolic Associations of Reduced Proliferation and Oxidative Stress in Advanced Breast Cancer

Matej Oresic, Eytan Ruppin, Carsten Denkert, 2012 .

Diagnostic and therapeutic implications of tumor-infiltrating lymphocytes in breast cancer.

C. Denkert, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A prognostic gene expression index in ovarian cancer—validation across different independent data sets

W. Weichert, C. Denkert, M. Dietel, 2009, The Journal of pathology.

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

P. Fasching, C. Denkert, W. Eiermann, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors.

O. Fiehn, W. Weichert, C. Denkert, 2006, Cancer research.

Overexpression of the Embryonic-Lethal Abnormal Vision-like Protein HuR in Ovarian Carcinoma Is a Prognostic Factor and Is Associated with Increased Cyclooxygenase 2 Expression

W. Weichert, C. Denkert, M. Dietel, 2004, Cancer Research.

Polo-like kinase 1 expression is a prognostic factor in human colon cancer.

W. Weichert, G. Kristiansen, C. Denkert, 2005, World journal of gastroenterology.

Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer

A. Tutt, L. Pusztai, C. Denkert, 2012, Annals of Surgical Oncology.

Uterine Arterial Embolization With Tris-acryl Gelatin Microspheres: A Histopathologic Evaluation

B. Hamm, W. Weichert, C. Denkert, 2005, The American journal of surgical pathology.

Loss-of-function uORF mutations in human malignancies

Tabea G. Kischka, C. Denkert, M. Andrade-Navarro, 2018, Scientific Reports.

Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients - a study of the OVCAD consortium

Theresia Thalhammer, Carsten Denkert, Georg Heinze, 2013, BMC Cancer.

Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

Carsten Denkert, Jan Budczies, Wilko Weichert, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC).

M. Rezai, P. Fasching, A. Schneeweiss, 2017 .

Comprehensive analysis of clinico-pathological data reveals heterogeneous relations between atherosclerosis and cancer

Carsten Denkert, Jan Budczies, Volker Endris, 2014, Journal of Clinical Pathology.

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothe

Carsten Denkert, Fred Hirsch, Benjamin Solomon, 2017, Advances in anatomic pathology.

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

J. Cuzick, A. Tutt, C. Denkert, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis.

Carsten Denkert, Thomas Beckers, Wilko Weichert, 2008, The Lancet. Oncology.

TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO-001 Trial

C. Denkert, J. Budczies, F. Klauschen, 2020, Clinical Cancer Research.

Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial

P. Fasching, A. Schneeweiss, W. Weichert, 2018, Clinical Cancer Research.

Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer

Peter A. Fasching, Carsten Denkert, Mahdi Rezai, 2016, Clinical Cancer Research.

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.

S Michiels, C Desmedt, C Sotiriou, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.

Carsten Denkert, Peter A Fasching, Andreas Schneeweiss, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization

Carsten Denkert, Jan Budczies, Frederick Klauschen, 2012, PloS one.

Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences

Carsten Denkert, Jan Budczies, Nicole Pfarr, 2014, Oncotarget.

Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement.

S Michiels, C Sotiriou, G Viale, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance

M Hummel, M Dietel, C Denkert, 2013, Cancer Gene Therapy.

Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group

Carsten Denkert, Jan Budczies, David L Rimm, 2016, Modern Pathology.

Expression of mitogen‐activated protein kinase phosphatase‐1 (MKP‐1) in primary human ovarian carcinoma

Steffen Hauptmann, Carsten Denkert, Manfred Dietel, 2002, International journal of cancer.

Genome-wide Gene Expression Profiling of Formalin-fixed Paraffin-Embedded Breast Cancer Core Biopsies Using Microarrays

Carsten Denkert, Jan Budczies, Wilko Weichert, 2011, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials

Jacqueline A. Hall, Sarah N. Dudgeon, A. Gown, 2020, npj Breast Cancer.

DNA methylation profiling reliably distinguishes pulmonary enteric adenocarcinoma from metastatic colorectal cancer

C. Denkert, F. Klauschen, D. Lenze, 2019, Modern Pathology.

A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial

P. Fasching, T. Fehm, C. Denkert, 2020, Clinical Cancer Research.

stress in advanced breast cancer Metabolic associations of reduced proliferation and oxidative Updated

E. Ruppin, C. Denkert, G. Stein, 2012 .

MEK 1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer

C. Denkert, A. Lánczky, Zsófia Pénzváltó, 2014 .

MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer

C. Denkert, A. Lánczky, B. Győrffy, 2014, BMC Cancer.

Cyclin-dependant kinase inhibitors CIP1 (p21) and KIP1 (p27) in ovarian cancer

C. Denkert, A. Reles, W. Lichtenegger, 2006, Journal of Cancer Research and Clinical Oncology.

Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study.

C. Denkert, W. Eiermann, F. Marmé, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Intraductal papillomas of the breast: diagnosis and management of 151 patients.

C. Denkert, A. Schneider, C. Richter-Ehrenstein, 2011, Breast.

Outcome of breast cancer patients with low hormone receptor positivity: Analysis of a 15-year population-based cohort.

W. Weichert, C. Denkert, M. Kiechle, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Influence of CYP2D6-genotype on tamoxifen efficacy in advanced breast cancer

C. Denkert, K. Possinger, A. Regierer, 2013, Breast Cancer Research and Treatment.

Oestrogen receptor 1 mRNA is a prognostic factor in ovarian cancer patients treated with neo-adjuvant chemotherapy: determination by array and kinetic PCR in fresh tissue biopsies.

C. Denkert, M. Dietel, R. Wirtz, 2009, Endocrine-related cancer.

Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765)

C. Denkert, H. Ulmer, R. Wirtz, 2011, Breast Cancer Research and Treatment.

Induction of G0/G1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interference

A. Fürstenberg, W. Weichert, C. Denkert, 2003, Oncogene.

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

E. Winer, J. Cuzick, A. Tutt, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic impact of cyclooxygenase-2 in breast cancer.

Steffen Hauptmann, Carsten Denkert, K. Winzer, 2004, Clinical breast cancer.

Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer.

C. Denkert, M. Dietel, H. Tesch, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Tumor-infiltrating lymphocytes in breast cancer

C. Denkert, S. Loibl, G. von Minckwitz, 2014, Oncoimmunology.

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

E. Winer, J. Cuzick, A. Tutt, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of Multifocal or Multicentric Disease on Surgery and Locoregional, Distant and Overall Survival of 6,134 Breast Cancer Patients Treated With Neoadjuvant Chemotherapy

M. Rezai, C. Denkert, T. Kühn, 2015, Annals of Surgical Oncology.

Estrogen receptor 1 mRNA is a prognostic factor in ovarian carcinoma: determination by kinetic PCR in formalin-fixed paraffin-embedded tissue.

Carsten Denkert, Jan Budczies, Wilko Weichert, 2009, Endocrine-related cancer.

Evaluation of a hormone receptor‐positive ovarian carcinoma subtype with a favourable prognosis by determination of progesterone receptor and oestrogen receptor 1 mRNA expression in formalin‐fixed paraffin‐embedded tissue

C. Denkert, M. Dietel, J. Budczies, 2011, Histopathology.

Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto

M. Rezai, P. Fasching, A. Schneeweiss, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

pT but not pN stage of the 8th TNM classification significantly improves prognostication in pancreatic ductal adenocarcinoma.

H. Friess, W. Weichert, C. Denkert, 2017, European journal of cancer.

PG 7.04 Developing Ki67 as a useful marker

C. Denkert, 2015 .

Reply to Ki67 in breast cancer: a useful prognostic marker!

C. Denkert, G. von Minckwitz, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Tissue-Based Metabolomics to Analyze the Breast Cancer Metabolome.

C. Denkert, J. Budczies, 2016, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial

P. Fasching, A. Schneeweiss, C. Denkert, 2022, Cancers.

Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus

P. Fasching, A. Schneeweiss, C. Denkert, 2021, Geburtshilfe und Frauenheilkunde.

Prospective, Multicenter, Randomized Phase III Trial Evaluating the Impact of Lymphoscintigraphy as Part of Sentinel Node Biopsy in Early Breast Cancer: SenSzi (GBG80) Trial.

M. Rezai, C. Denkert, J. Heil, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gallen-Konsensuskonferenz ( Wien 2017 ) Initial Treatment of Patients with Primary Breast Cancer : Evidence , Controversies , Consensus Spectrum of Opinion of German Specialists at the 15 th International St . Gallen Breast Cancer Conference ( Vienna 2017 )

P. Fasching, T. Fehm, A. Schneeweiss, 2017 .

Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017).

P. Fasching, T. Fehm, A. Schneeweiss, 2017, Geburtshilfe und Frauenheilkunde.

Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus Erstbehandlung von Patientinnen mit primärem Mammakarzinom: Evidenz, Kontroversen, Konsens

P. Fasching, T. Fehm, A. Schneeweiss, 2017, Geburtshilfe und Frauenheilkunde.

Reactive stroma and trastuzumab resistance in HER2‐positive early breast cancer

C. Sotiriou, S. Loi, C. Denkert, 2020, International journal of cancer.

PARP-1 expression as a prognostic factor in Desmoid-type fibromatosis.

C. Denkert, J. Budczies, P. Wust, 2019, Annals of diagnostic pathology.

Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer

C. Denkert, F. Marmé, S. Loibl, 2018, Breast Cancer Research and Treatment.

Clinical relevance and concordance of HER2 status in local and central testing—an analysis of 1581 HER2-positive breast carcinomas over 12 years

M. Rezai, A. Schneeweiss, C. Denkert, 2017, Modern Pathology.

KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology.

W. Weichert, A. Stenzinger, C. Denkert, 2010, The Journal of molecular diagnostics : JMD.

Applicability of a System for Fully Automated Nucleic Acid Extraction From Formalin-fixed Paraffin-embedded Sections for Routine KRAS Mutation Testing

W. Weichert, C. Denkert, M. Dietel, 2012, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

A Non-interventional Clinical Trial Assessing Immune Responses After Radiofrequency Ablation of Liver Metastases From Colorectal Cancer

H. Rammensee, S. Stevanović, P. Pereira, 2019, Front. Immunol..

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

Andrew H. Beck, Jacqueline A. Hall, Sarah N. Dudgeon, 2020, npj Breast Cancer.

Detection and diagnosis

P. Neven, C. Denkert, M. Dietel, 2012 .

Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial.

P. Fasching, A. Schneeweiss, C. Denkert, 2022, JAMA oncology.

Prioritization of metabolic genes as novel therapeutic targets in estrogen-receptor negative breast tumors using multi-omics data and text mining

O. Fiehn, C. Denkert, J. Budczies, 2019, bioRxiv.

Response-based molecular subtyping-emergence of the third generation of breast cancer subtypes.

C. Denkert, S. Loibl, 2022, Cancer cell.

Preoperative transvaginal ultrasound (TVS) in the description of pelvic tumor spread in endometrial cancer: results of a prospective study.

C. Denkert, W. Henrich, C. Wolf, 2008, Anticancer research.

Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials

P. Fasching, A. Schneeweiss, C. Denkert, 2017, Breast Cancer Research and Treatment.

The immunogenicity of breast cancer--molecular subtypes matter.

C. Denkert, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Post‐neoadjuvant assessment of tumour budding according to ITBCC subgroups delivers stage‐ and regression‐grade independent prognostic information in intestinal‐type gastric adenocarcinoma

W. Weichert, C. Denkert, A. Hapfelmeier, 2022, The journal of pathology. Clinical research.

Prognostic value of regulatory T cells and T helper 17 cells in high grade serous ovarian carcinoma

C. Denkert, W. Schmitt, J. Sehouli, 2022, Journal of Cancer Research and Clinical Oncology.

Loss of SATB2 Occurs More Frequently Than CDX2 Loss in Colorectal Carcinoma and Identifies Particularly Aggressive Cancers in High-Risk Subgroups

W. Weichert, C. Denkert, P. Jank, 2021, Cancers.

pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy - A retrospective pooled analysis of individual patients data of four German neoadjuvant trials.

A. Schneeweiss, C. Denkert, S. Loibl, 2017, Breast.

Cellular and soluble immune checkpoint signaling forms PD-L1 and PD-1 in renal tumor tissue and in blood

C. Denkert, J. Hänze, A. Hegele, 2022, Cancer Immunology, Immunotherapy.

Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma

C. Denkert, M. Dietel, J. Budczies, 2015, Oncotarget.

Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes

C. Denkert, M. Dietel, S. Loibl, 2014, BMC Cancer.

RNA-based determination of ESR1 and HER2 expression and response to neoadjuvant chemotherapy.

C. Denkert, M. Dietel, J. Budczies, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Characteristics and Clinical Outcome of Breast Cancer Patients with Asymptomatic Brain Metastases

P. Fasching, T. Fehm, C. Denkert, 2020, Cancers.

[Molecular profiling and predictive signatures. Biomarker analysis in ovarian cancer].

C. Denkert, 2008, Der Pathologe.

Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy.

P. Fasching, C. Denkert, H. Tesch, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Morphology and tumour‐infiltrating lymphocytes in high‐stage, high‐grade serous ovarian carcinoma correlated with long‐term survival

C. Denkert, I. Vergote, S. Wienert, 2018, Histopathology.

Reply to L. Ozretić et al

C. Denkert, S. Loibl, B. Müller, 2011 .

PARP expression in early breast cancer and its predictive value for response to neoadjuvant chemotherapy.

C. Denkert, J. Budczies, S. Loibl, 2010 .

443 PARP is expressed in all subtypes of early breast cancer and is a predictive factor for response to neoadjuvant chemotherapy

C. Denkert, J. Budczies, S. Loibl, 2010 .

Flat epithelial atypia is a common subtype of B3 breast lesions and is associated with noninvasive cancer but not with invasive cancer in final excision histology.

W. Weichert, C. Denkert, M. Dietel, 2010, Human pathology.

Overexpression of the plasminogen activator inhibitor type-1 in epithelial ovarian cancer.

C. Denkert, W. Lichtenegger, J. Sehouli, 2006, Anticancer research.

Hypoxia-mediated alterations and their role in the HER-2/neuregulated CREB status and localization

C. Denkert, B. Seliger, D. Mougiakakos, 2016, Oncotarget.

Neoadjuvant treatment of breast cancer--Clinical and research perspective.

C. Denkert, S. Loibl, G. von Minckwitz, 2015, Breast.

Expression of cyclooxygenase 2 in human malignant melanoma.

C. Denkert, S. Hauptmann, M. Köbel, 2001, Cancer research.

Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29).

M. Rezai, P. Fasching, A. Schneeweiss, 2016, European journal of cancer.

Protein kinase C isoform expression in ovarian carcinoma correlates with indicators of poor prognosis.

W. Weichert, C. Denkert, M. Dietel, 2003, International journal of oncology.

Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - Results from the CONKO-001 trial.

C. Denkert, H. Oettle, H. Riess, 2015, European journal of cancer.

Tumor in ﬁ ltrating lymphocyte strati ﬁ cation of prognostic staging of early-stage triple negative breast cancer

R. Gray, C. Sotiriou, S. Loi, 2021 .

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

Andrew H. Beck, Jacqueline A. Hall, A. Beck, 2020, npj Breast Cancer.

Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019.

E. Winer, C. Denkert, M. Gnant, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials

Jacqueline A. Hall, Sarah N. Dudgeon, A. Gown, 2020, npj Breast Cancer.

Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy.

C. Denkert, M. Dietel, J. Budczies, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Integration of metabolomics and expression of glycerol-3-phosphate acyltransferase (GPAM) in breast cancer-link to patient survival, hormone receptor status, and metabolic profiling.

Oliver Fiehn, Carsten Denkert, Jan Budczies, 2012, Journal of proteome research.

[NF-kappaB subunit p65/RelA expression in ovarian carcinoma: prognostic impact and link to COX-2 overexpression].

W. Weichert, C. Denkert, M. Dietel, 2007, Verhandlungen der Deutschen Gesellschaft fur Pathologie.

Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer: alterations in glutamine and beta-alanine metabolism.

Oliver Fiehn, Carsten Denkert, Jan Budczies, 2013, Journal of proteomics.

Glutamate enrichment as new diagnostic opportunity in breast cancer

O. Fiehn, K. Winzer, C. Denkert, 2015, International journal of cancer.

Molecular and Cellular Pathobiology Novel Theranostic OpportunitiesOffered byCharacterization of Altered Membrane Lipid Metabolism in Breast Cancer Progression

O. Fiehn, C. Denkert, J. Budczies, 2011 .

Predictive value of sphingosine kinase-1 expression in neoadjuvant treatment of breast cancer.

C. Denkert, V. Nekljudova, G. von Minckwitz, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study

A. Gown, S. Leung, T. Nielsen, 2022, Modern Pathology.

Impact in delay of start of chemotherapy and surgery on pCR and survival in breast cancer: A pooled analysis of individual patient data from six prospectively randomized neoadjuvant trials.

P. Fasching, A. Schneeweiss, C. Denkert, 2017 .

High nuclear poly‐(ADP‐ribose)‐polymerase expression is prognostic of improved survival in pancreatic cancer

A. Stenzinger, C. Denkert, M. Dietel, 2012, Histopathology.

Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement.

T. Sørlie, M. J. van de Vijver, C. Sotiriou, 2012 .

Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al.

E. Winer, J. Cuzick, A. Tutt, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract S2-07: A randomized phase III trial comparing neoadjuvant chemotherapy with weekly nanoparticle-based paclitaxel with solvent-based paclitaxel followed by anthracyline/cyclophosphamide for patients with early breast cancer (GeparSepto); GBG 69

A. Schneeweiss, C. Denkert, S. Loibl, 2015 .

Comparison of risk assessment in 1652 early ER positive, HER2 negative breast cancer in a real-world data set: classical pathological parameters vs. 12-gene molecular assay (EndoPredict)

C. Denkert, P. Jank, W. Schmitt, 2021, Breast Cancer Research and Treatment.

Practice-Changing Perspectives regarding Systemic Therapy in Early Breast Cancer: Opinions of German Experts regarding the 17th St. Gallen International Consensus Conference

P. Fasching, A. Schneeweiss, C. Denkert, 2022, Breast Care.

Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials

A. Schneeweiss, C. Denkert, J. Heil, 2019, Annals of Surgical Oncology.

Establishment of a new valid animal model for the evaluation of hyperthermic intraperitoneal chemotherapy (HIPEC) in pediatric rhabdomyosarcoma

C. Denkert, P. Jank, A. Mahnken, 2021, Pediatric blood & cancer.

Hotspot ESR1 mutations are multimodal and contextual modulators of breast cancer metastasis.

Adrian V. Lee, Simon C Watkins, G. Tseng, 2022, Cancer research.

Combined Focused Next-Generation Sequencing Assays to Guide Precision Oncology in Solid Tumors: A Retrospective Analysis from an Institutional Molecular Tumor Board

C. Denkert, C. Görg, A. Neubauer, 2022, Cancers.

SPARC expression in resected pancreatic cancer patients treated with Gemcitabine: results from the CONKO-001 study.

B. Dörken, C. Denkert, M. Dietel, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Increasing the efficiency of hyperthermic intraperitoneal chemotherapy (HIPEC) by combination with a photosensitive drug in pediatric rhabdomyosarcoma in an animal model

C. Denkert, P. Jank, G. Seitz, 2022 .

Cellular and soluble immune checkpoint signaling forms PD-L1 and PD-1 in renal tumor tissue and in blood

C. Denkert, J. Hänze, A. Hegele, 2022, Cancer Immunology, Immunotherapy.

Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast

P. Fasching, A. Schneeweiss, C. Denkert, 2021, European Journal of Cancer.

NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto.

P. Fasching, A. Schneeweiss, C. Denkert, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Significance of cyclooxygenase 2 and MDR1/P-glycoprotein coexpression in ovarian cancers.

C. Denkert, M. Dietel, M. Zabel, 2006, Cancer letters.

Increased Density of Growth Differentiation Factor-15+ Immunoreactive M1/M2 Macrophages in Prostate Cancer of Different Gleason Scores Compared with Benign Prostate Hyperplasia

C. Denkert, R. Kinscherf, J. Hänze, 2022, Cancers.

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

R. Bernards, C. Sotiriou, S. Loi, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

R. Bernards, C. Sotiriou, S. Loi, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study

B. Dörken, C. Denkert, H. Oettle, 2014, British Journal of Cancer.

Hent1 expression in patients with pancreatic cancer treated with gemcitabine after curative intended resection: Results from the CONKO-001 trial.

B. Dörken, C. Denkert, H. Oettle, 2014 .

Neuroendocrine Differentiation in Conventional Colorectal Adenocarcinomas: Incidental Finding or Prognostic Biomarker?

W. Weichert, K. Schwamborn, C. Denkert, 2021, Cancers.

Frequency and Prognostic Significance of Intertumoural Heterogeneity in Multifocal Jejunoileal Neuroendocrine Tumours

C. Denkert, D. Bartsch, A. Ramaswamy, 2022, Cancers.

Cellular dissociation grading on biopsies of pulmonary squamous cell carcinoma provides prognostic information across all stages and is congruent with resection specimen grading

M. Kriegsmann, A. Warth, W. Weichert, 2022, The journal of pathology. Clinical research.

Rearranged Epstein-Barr Virus Genome in Hodgkin’s Disease and Angioimmunoblastic Lymphadenopathy: Swiss

C. Denkert, S. Hauptmann, 2003 .

Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas.

W. Weichert, C. Denkert, M. Dietel, 2008, Neoplasia.

Management von Borderlinetumoren des Ovars (BOT)

C. Denkert, M. Dietel, W. Lichtenegger, 2005, Der Onkologe.

Biomarker data from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer.

P. Fasching, C. Denkert, Chiun-Sheng Huang, 2020 .

Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer.

S. Loi, C. Denkert, S. Loibl, 2022, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Correlation of PIK3CA mutation with pathological complete response in primary HER2-positive breast cancer: Combined analysis of 967 patients from three prospective clinical trials.

C. Sotiriou, S. Loi, C. Denkert, 2015 .

Abstract PD5-7: PTEN andPIK3CAbut not p4EBP1 are associated with low rates of pathological complete response (pCR) to trastuzumab based chemotherapy in primary HER2-overexpressing breast cancer

P. Fasching, C. Denkert, S. Loibl, 2015 .

Validation of p95 as a predictive marker for trastuzumab-based therapy in primary HER2-positive breast cancer: A translational investigation from the neoadjuvant GeparQuattro study.

T. Fehm, C. Denkert, H. Tesch, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

pT3 colorectal cancer revisited: a multicentric study on the histological depth of invasion in more than 1000 pT3 carcinomas—proposal for a new pT3a/pT3b subclassification

W. Weichert, C. Denkert, I. Nagtegaal, 2022, British Journal of Cancer.

Differential gene expression of urokinase-type plasminogen activator and its receptor in human renal cell carcinoma.

S. Loening, G. Kristiansen, C. Denkert, 2005, Oncology reports.

Cytokine-suppressive anti-inflammatory drugs (CSAIDs) inhibit invasion and MMP-1 production of ovarian carcinoma cells.

C. Denkert, S. Hauptmann, M. Köbel, 2003, Cancer letters.

Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference - Substudy of the randomised phase III GAIN-2 study

C. Denkert, F. Marmé, S. Loibl, 2022, Breast.

Predicting Prognosis of Breast Cancer Patients with Brain Metastases in the BMBC Registry—Comparison of Three Different GPA Prognostic Scores

T. Fehm, C. Denkert, T. Park-Simon, 2020, Cancers.

The journey of tumor infiltrating lymphocytes (TIL) as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition.

S. Loi, C. Denkert, J. Budczies, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials.

P. Fasching, A. Schneeweiss, C. Denkert, 2021, European journal of cancer.

S3-2: Neoadjuvant Chemotherapy Adapted by Interim Response Improves Overall Survival of Primary Breast Cancer Patients - Results of the GeparTrio Trial.

A. Schneeweiss, C. Denkert, W. Eiermann, 2011 .

VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC

P. Fasching, L. Pusztai, C. Denkert, 2021 .

[Immunoncology and tumor infiltrating lymphocytes-new strategies for therapy and diagnosis of breast cancer].

C. Denkert, 2020, Der Pathologe.

Neoadjuvant chemotherapy in operable breast cancer with docetaxel, doxorubicin, and cyclophosphamide (TAC) or TAC followed by vinorelbine and capecitabine (NX): Final results and analysis of markers predicting response to treatment.

C. Denkert, G. von Minckwitz, J. Huober, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Matrix stiffness drives stromal autophagy and promotes formation of a protumorigenic niche

C. Denkert, A. Visekruna, P. Pfefferle, 2021, Proceedings of the National Academy of Sciences.

A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52)

C. Denkert, W. Eiermann, F. Marmé, 2015, Cancer.

Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro).

M. Rezai, P. Fasching, A. Schneeweiss, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Deep learning for fully-automated nuclear pleomorphism scoring in breast cancer

J. A. van der Laak, M. Balkenhol, P. Bult, 2022, npj Breast Cancer.

Homologous recombination deficiency (HRD) as an ovarian cancer biomarker in a real-world cohort - validation of decentralized genomic profiling.

C. Denkert, F. Marmé, P. Jank, 2022, The Journal of molecular diagnostics : JMD.

Validation of a Nomogram Predicting Non-Sentinel Lymph Node Metastases among Patients with Breast Cancer after Primary Systemic Therapy - a transSENTINA Substudy

T. Fehm, C. Denkert, T. Kühn, 2018, Breast Care.

Regulation of cell growth and the expression of extracellular matrix proteins in colorectal adenocarcinoma: a fibroblast-tumor cell coculture model to study tumor-host interactions in vitro.

C. Denkert, S. Hauptmann, M. Köbel, 2003, European journal of cell biology.

EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy

P. Fasching, C. Denkert, F. Marmé, 2022, BMC Cancer.

Suppression of the reactive oxygen intermediates production of human macrophages by colorectal adenocarcinoma cell lines

C. Denkert, S. Hauptmann, A. Siegert, 1999, Immunology.

Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer: A Secondary Analysis of the GeparOcto Randomized Clinical Trial.

P. Fasching, A. Schneeweiss, C. Denkert, 2020, JAMA oncology.

HER2-low-positive breast cancer from four neoadjuvant clinical trials - Authors' reply.

C. Denkert, S. Loibl, V. Nekljudova, 2021, The Lancet. Oncology.

Response-guided neoadjuvant chemotherapy for breast cancer.

Carsten Denkert, Andreas Schneeweiss, Stefan Paepke, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy.

P. Fasching, A. Schneeweiss, C. Denkert, 2021, European journal of cancer.

Prognostic and predictive impact of Ki-67 before and after neoadjuvant chemotherapy on PCR and survival: Results of the GeparTrio trial.

T. Fehm, C. Denkert, W. Eiermann, 2012 .

S5-4: pCR as a Surrogate in HER2−Positive Patients Treated with Trastuzumab.

P. Fasching, C. Denkert, S. Loibl, 2011 .

GeparOLA: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer (BC) and homologous recombination deficiency (H

P. Fasching, A. Schneeweiss, C. Denkert, 2019, Journal of Clinical Oncology.

Immunophenotype and proliferation to predict for response to neoadjuvant chemotherapy in TNBC: Results from BrighTNess phase III study.

C. Denkert, M. Watson, W. Symmans, 2019, Journal of Clinical Oncology.

A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE)

C. Denkert, N. Burchardi, V. Nekljudova, 2022, ESMO open.

Selecting patients with HER2-low breast cancer: Getting out of the tangle.

C. Denkert, J. Lennerz, J. Bartlett, 2022, European journal of cancer.

Reply to F. Bellati et al

C. Denkert, S. Loibl, G. Minckwitz, 2010 .

IMP3 Expression in Human Ovarian Cancer is Associated With Improved Survival

W. Weichert, C. Denkert, M. Dietel, 2009, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

Nitric oxide of human colorectal adenocarcinoma cell lines promotes tumour cell invasion

C. Denkert, S. Hauptmann, W. Schmitt, 2002, British Journal of Cancer.

Fulminant intravascular disseminating malignant melanoma mimicking acute leukemia.

C. Denkert, K. Possinger, W. Sterry, 1999, Blood.

DNA methylation-based classification of sinonasal tumors

David C. Jones, F. Heppner, C. Denkert, 2022, Nature Communications.

Systematic Evaluation of the Intraoperative Tumor Pattern in Patients With Borderline Tumor of the Ovary

C. Denkert, W. Lichtenegger, J. Sehouli, 2009, International Journal of Gynecologic Cancer.

Melanoma Expression of Cyclooxygenase 2 in Human Malignant

C. Denkert, S. Hauptmann, M. Köbel, 2000 .

MALDI‐Imaging for Classification of Epithelial Ovarian Cancer Histotypes from a Tissue Microarray Using Machine Learning Methods

Carsten Denkert, Jan Lellmann, Herbert Thiele, 2018, Proteomics. Clinical applications.

Role of histological type on surgical outcome and survival following radical primary tumour debulking of epithelial ovarian, fallopian tube and peritoneal cancers

C. Denkert, J. Sehouli, C. Fotopoulou, 2011, British Journal of Cancer.

Deregulation of hydroxybutyric acid metabolism provides diagnostic and prognostic biomarkers in ovarian high-grade serous carcinomas

F. Markowetz, T. Aittokallio, C. Denkert, 2016 .

Abstract S3-1: Neoadjuvant Chemotherapy in the very young 35 years of age or younger

A. Schneeweiss, C. Denkert, S. Loibl, 2012 .

New treatment options for metastatic HER2-low breast cancer : Consequences for histopathological diagnosis.

C. Denkert, A. Lebeau, C. Jackisch, 2022, Pathologie.

Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells.

Carsten Denkert, Jan Budczies, Manfred Dietel, 2009, Cancer research.

Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer - overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression

W. Weichert, K. Winzer, C. Denkert, 2013, BMC Cancer.

Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations

C. Denkert, M. Dietel, B. Györffy, 2006, International journal of cancer.

Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy

W. Weichert, K. Schlüns, C. Denkert, 2009, Breast Cancer Research.

Patients with metastatic hormone receptor-positive breast cancer express PIK3CA oncogene mutational heterogeneity in circulating tumor cells

C. Denkert, P. Dam, R. Salgado, 2016 .

Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group

M. Ellis, S. Leung, T. Nielsen, 2020, Journal of the National Cancer Institute.

Would Virchow be a systems biologist? A discourse on the philosophy of science with implications for pathological research

W. Weichert, A. Stenzinger, C. Denkert, 2010, Virchows Archiv.

Disseminated Mucormycosis Caused by Absidia corymbifera Leading to Cerebral Vasculitis

C. Denkert, W. Brück, O. Sezer, 2000, Infection.

Actinomycotic inflammatory disease and misdiagnosis of ovarian cancer. A case report.

C. Denkert, M. Dietel, W. Henrich, 2006, Anticancer research.

Breast cancer

C. Denkert, M. Morrow, S. Loibl, 2021, The Lancet.

Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy

W. Weichert, G. Kristiansen, C. Denkert, 2008, British Journal of Cancer.

Linking CREB function with altered metabolism in murine fibroblast-based model cell lines

C. Denkert, B. Seliger, D. Mougiakakos, 2017, Oncotarget.

Clinical relevance of host immunity in breast cancer: from TILs to the clinic

Carsten Denkert, Christos Sotiriou, Mark J. Smyth, 2016, Nature Reviews Clinical Oncology.

Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.

Carsten Denkert, Stefan Michiels, Christos Sotiriou, 2015, JAMA oncology.

RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

S. Mallal, R. Yelensky, S. Loi, 2015, Clinical Cancer Research.

Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo.

P. Fasching, A. Schneeweiss, C. Denkert, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Molecular alterations in triple-negative breast cancer—the road to new treatment strategies

C. Denkert, A. Tutt, C. Liedtke, 2017, The Lancet.

Down‐regulation of the microRNA processing enzyme Dicer is a prognostic factor in human colorectal cancer

W. Weichert, A. Stenzinger, C. Denkert, 2012, Histopathology.

Prognostic significance of Dicer expression in ovarian cancer—link to global microRNA changes and oestrogen receptor expression

W. Weichert, C. Denkert, M. Dietel, 2009, The Journal of pathology.

Metabolite profiling of human colon carcinoma – deregulation of TCA cycle and amino acid turnover

Oliver Fiehn, Tobias Kind, Carsten Denkert, 2008, Molecular Cancer.

A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance

M Hummel, M Dietel, F Klauschen, 2015, Cancer Gene Therapy.

Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials

A. Schneeweiss, P. Neven, C. Denkert, 2015, Breast Cancer Research and Treatment.

Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021

E. Rutgers, M. Piccart, C. Denkert, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness

C. Denkert, W. Symmans, H. Rugo, 2021, npj Breast Cancer.

Association of RAD51 with Homologous Recombination Deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial.

P. Fasching, A. Schneeweiss, C. Denkert, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane–Based Neoadjuvant Chemotherapy

C. Denkert, S. Loibl, G. von Minckwitz, 2020, Cancer research and treatment : official journal of Korean Cancer Association.

Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance

G. Mills, R. Bernards, C. Sotiriou, 2016, Clinical Cancer Research.

Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer

P. Fasching, C. Denkert, S. Loibl, 2016, Clinical Cancer Research.

TITLE: INTEGRATED ANALYSIS OF PTEN AND p4EBP1 PROTEIN EXPRESSION AS PREDICTORs FOR pCR IN HER2 POSITIVE BREAST CANCER

P. Fasching, C. Denkert, S. Loibl, 2015 .

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.

M. Rezai, P. Fasching, A. Schneeweiss, 2014, The Lancet. Oncology.

Mutation patterns in genes encoding interferon signaling and antigen presentation: A pan‐cancer survey with implications for the use of immune checkpoint inhibitors

S. Fröhling, P. Schirmacher, A. Stenzinger, 2017, Genes, chromosomes & cancer.

An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer

John M S Bartlett, Liron Pantanowitz, Carsten Denkert, 2018, Modern Pathology.

The landscape of metastatic progression patterns across major human cancers

Carsten Denkert, Jan Budczies, Michael Bockmayr, 2014, Oncotarget.

Pembrolizumab for Early Triple-Negative Breast Cancer.

P. Fasching, J. Bergh, L. Pusztai, 2020, The New England journal of medicine.

Tumor infiltrating lymphocytes in early breast cancer.

C. Denkert, G. Pruneri, A. Vingiani, 2018, Breast.

Abstract S4-06: PIK3CA mutation predicts resistance to anti-HER2/chemotherapy in primary HER2-positive/hormone-receptor-positive breast cancer – Prospective analysis of 737 participants of the GeparSixto and GeparQuinto studies

M. Rezai, P. Fasching, A. Schneeweiss, 2013 .

Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.

Carsten Denkert, Stephan Wienert, Frederick Klauschen, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy

Carsten Denkert, Keyur Mehta, Bernd Gerber, 2011, Breast Cancer Research and Treatment.

What turns CREB on? And off? And why does it matter?

C. Denkert, J. Budczies, B. Seliger, 2020, Cellular and Molecular Life Sciences.

The orphan nuclear receptors, estrogen receptor-related receptors: their role as new biomarkers in gynecological cancer.

C. Denkert, W. Lichtenegger, J. Sehouli, 2006, Anticancer research.

Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy.

P. Fasching, A. Schneeweiss, C. Denkert, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden

M. Kloor, P. Schirmacher, A. Stenzinger, 2018, Oncoimmunology.

PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma

S. Fröhling, P. Schirmacher, A. Stenzinger, 2017, Oncoimmunology.

Pan‐cancer analysis of copy number changes in programmed death‐ligand 1 (PD‐L1, CD274) – associations with gene expression, mutational load, and survival

Maristela L Onozato, S. Fröhling, A. Iafrate, 2016, Genes, chromosomes & cancer.

Expression of the ELAV-like protein HuR in human colon cancer: association with tumor stage and cyclooxygenase-2

W. Weichert, C. Denkert, M. Dietel, 2006, Modern Pathology.

Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.

Heikki Joensuu, Carsten Denkert, Damien Drubay, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Elevated expression of cyclooxygenase‐2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma

W. Weichert, G. Kristiansen, K. Winzer, 2003, Cancer.

Acquired mutations and transcriptional remodeling in long-term estrogen-deprived locoregional breast cancer recurrences

Adrian V. Lee, C. Denkert, S. Oesterreich, 2020, bioRxiv.

Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network.

C. Denkert, J. Budczies, P. Jank, 2019, Human pathology.

Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma

C. Denkert, M. Dietel, S. Loibl, 2017, Virchows Archiv.

Wilms tumor protein 1 (WT1)-- not only a diagnostic but also a prognostic marker in high-grade serous ovarian carcinoma.

C. Denkert, M. Dietel, S. Darb-Esfahani, 2016, Gynecologic oncology.

Ambivalent role of pFAK-Y397 in serous ovarian cancer-a study of the OVCAD consortium

C. Denkert, R. Zeillinger, I. Vergote, 2014, Molecular Cancer.

HE4 tissue expression in borderline ovarian tumors: a pilot study by the tumorbank ovarian cancer network.

C. Denkert, S. Darb-Esfahani, J. Sehouli, 2013, Anticancer research.

Expression of classical NF‐κB pathway effectors in human ovarian carcinoma

C. Denkert, M. Dietel, B. Györffy, 2010, Histopathology.

The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

E. Perez, C. Sotiriou, S. Loi, 2021, NPJ breast cancer.

Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy

S. Loi, W. Weichert, A. Stenzinger, 2016, Oncotarget.

An illegitimate microRNA target site within the 3' UTR of MDM4 affects ovarian cancer progression and chemosensitivity.

C. Denkert, S. Hauptmann, J. Marine, 2010, Cancer research.

High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo

W. Weichert, G. Kristiansen, C. Denkert, 2009, BMC Cancer.

Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study).

P. Fasching, A. Schneeweiss, C. Denkert, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial

P. Fasching, A. Schneeweiss, C. Denkert, 2017, JAMA oncology.

Implementing HRD Testing in Routine Clinical Practice on Patients with Primary High-Grade Advanced Ovarian Cancer

C. Denkert, N. Concin, E. Hahnen, 2023, Cancers.

Analysis of PIK3CA Mutations in Breast Cancer Subtypes

Carsten Denkert, Jan Budczies, Manfred Dietel, 2014, Applied immunohistochemistry & molecular morphology : AIMM.

Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer

Rohit Bhargava, Carsten Denkert, Steffi Oesterreich, 2018, Molecular Cancer Research.

Author Correction: Loss-of-function uORF mutations in human malignancies

Tabea G. Kischka, C. Denkert, P. Schlag, 2018, Scientific Reports.

Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer

W. Weichert, G. Kristiansen, C. Denkert, 2008, BMC Cancer.

Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivo

W. Weichert, C. Denkert, M. Dietel, 2008, Clinical Cancer Research.

Ligneous cervicitis in a woman with plasminogen deficiency associated with an atypical form of microglandular hyperplasia: a case report and review of literature.

C. Denkert, M. Dietel, V. Chiantera, 2013, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

Specific inhibition of AKT2 by RNA interference results in reduction of ovarian cancer cell proliferation: increased expression of AKT in advanced ovarian cancer.

W. Weichert, C. Denkert, M. Dietel, 2007, Cancer letters.

Accumulated Metabolites of Hydroxybutyric Acid Serve as Diagnostic and Prognostic Biomarkers of Ovarian High-Grade Serous Carcinomas.

F. Markowetz, T. Aittokallio, C. Denkert, 2016, Cancer research.

Genetic alterations in epithelial ovarian tumors analyzed by comparative genomic hybridization.

S. Petersen, I. Petersen, K. Schlüns, 2002, Human pathology.

Hotspot ESR1 mutations are multimodal and contextual drivers of breast cancer metastasis

Adrian V. Lee, G. Tseng, C. Denkert, 2021, bioRxiv.

Activation of mTOR in a subgroup of ovarian carcinomas: correlation with p-eIF-4E and prognosis.

W. Weichert, C. Denkert, M. Dietel, 2008, Oncology reports.

A multicentre analytical comparison study of inter‐reader and inter‐assay agreement of four programmed death‐ligand 1 immunohistochemistry assays for scoring in triple‐negative breast cancer

W. Weichert, C. Denkert, M. Kiechle, 2020, Histopathology.

The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice

A. Gown, T. Nielsen, E. Thompson, 2020, The Journal of pathology.

Molecular HPV Typing as a Diagnostic Tool to Discriminate Primary From Metastatic Squamous Cell Carcinoma of the Lung

I. Petersen, W. Weichert, C. Denkert, 2009, The American journal of surgical pathology.

Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response

R. Eils, D. Jäger, A. Trumpp, 2017, Clinical Cancer Research.

Polycomb Protein BMI-1 as a Potential Therapeutic Target in Mucinous Ovarian Cancer

C. Denkert, P. Jank, S. Darb-Esfahani, 2022, AntiCancer Research.

Intra‐abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer

U. Neumann, C. Denkert, J. Sehouli, 2009, Journal of surgical oncology.

Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.

P. Fasching, A. Schneeweiss, C. Denkert, 2021, The Lancet. Oncology.

Cancer beyond organ and tissue specificity: Next‐generation‐sequencing gene mutation data reveal complex genetic similarities across major cancers

P. Hufnagl, P. Hufnagl, A. Stenzinger, 2014, International journal of cancer.

Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial

C. Sotiriou, P. Neven, S. Loi, 2015, Oncotarget.

How VEGF-A and its splice variants affect breast cancer development – clinical implications

C. Denkert, P. Jank, M. Karsten, 2022, Cellular Oncology.

Molecular Pathways Molecular Pathways : Involvement of ImmunePathways in the Therapeutic Response and Outcome in Breast Cancer

Carsten Denkert, Giuseppe Curigliano, Christos Sotiriou, 2012 .

Overexpression of Polo-Like Kinase 1 Is a Common and Early Event in Pancreatic Cancer

W. Weichert, G. Kristiansen, C. Denkert, 2005, Pancreatology.

Thymosin beta 15A (TMSB15A) is a predictor of chemotherapy response in triple-negative breast cancer

C. Denkert, M. Dietel, J. Budczies, 2012, British Journal of Cancer.

Semiconductor sequencing: how many flows do you need?

Carsten Denkert, Jan Budczies, Frederick Klauschen, 2015, Bioinform..

Expression of estrogen receptor-related receptors, a subfamily of orphan nuclear receptors, as new tumor biomarkers in ovarian cancer cells

C. Denkert, W. Lichtenegger, J. Sehouli, 2005, Journal of Molecular Medicine.

Tumour-Infiltrating Lymphocytes (TILs) in Breast Cancer: a Predictive or a Prognostic Marker?

S. Loi, C. Denkert, P. Savas, 2015, Current Breast Cancer Reports.

Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study

Anagha P. Jadhav, A. Gown, M. Ellis, 2022, Modern Pathology.

Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial.

A. Schneeweiss, C. Denkert, S. Loibl, 2016, The Lancet. Oncology.

Relationship between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic significance

C. Denkert, M. Dietel, R. Matkowski, 2005, Breast Cancer Research.

Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types

P. Schirmacher, A. Stenzinger, C. Denkert, 2017, BMC Medical Genomics.

Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) – Recommendations for Daily Routine Practice

P. Fasching, A. Schneeweiss, C. Denkert, 2019, Geburtshilfe und Frauenheilkunde.

RANK expression as a prognostic and predictive marker in breast cancer

C. Denkert, S. Loibl, M. Werner, 2014, Breast Cancer Research and Treatment.

Vascular CXCR4 Expression – a Novel Antiangiogenic Target in Gastric Cancer?

W. Weichert, C. Denkert, S. Schulz, 2010, PloS one.

Induction of apoptosis in the centre of multicellular tumour spheroids of colorectal adenocarcinomas—involvement of CD95 pathway and differentiation

S. Hauptmann, A. Leclere, C. Denkert, 1998, Apoptosis.

Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications

W. Weichert, G. Kristiansen, K. Winzer, 2005, Virchows Archiv.

Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma

W. Weichert, C. Denkert, M. Dietel, 2004, British Journal of Cancer.

Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer

P. Fasching, T. Fehm, C. Denkert, 2013, Clinical Cancer Research.

Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test

C. Denkert, M. Dietel, K. Weber, 2012, BMC Cancer.

Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma.

C. Denkert, H. Oettle, H. Riess, 2017, European journal of cancer.

Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro

W. Weichert, C. Denkert, M. Dietel, 2009, Journal of Cancer Research and Clinical Oncology.

Breast Cancer Diagnosed During Pregnancy: Adapting Recent Advances in Breast Cancer Care for Pregnant Patients.

C. Denkert, S. Loibl, G. von Minckwitz, 2015, JAMA oncology.

A GCIG international survey: clinical practice patterns of sentinel lymph node biopsies in cervical cancer

B. Monk, C. Denkert, J. Sehouli, 2019, Archives of Gynecology and Obstetrics.

Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes

C. Denkert, M. Dietel, S. Loibl, 2014, BMC Cancer.

Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer

W. Weichert, G. Kristiansen, K. Winzer, 2006, Journal of Clinical Pathology.

Who Is at Risk for Diagnostic Discrepancies? Comparison of Pre- and Postmortal Diagnoses in 1800 Patients of 3 Medical Decades in East and West Berlin

W. Weichert, A. Stenzinger, C. Denkert, 2012, PloS one.

Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer

M. Lux, M. Beckmann, P. Fasching, 2018, Geburtshilfe und Frauenheilkunde.

Efficacy and safety of nab-paclitaxel 125 mg/m2 and nab-paclitaxel 150 mg/m2 compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69)

A. Schneeweiss, C. Denkert, S. Loibl, 2017, Breast Cancer Research and Treatment.

HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer

P. Fasching, C. Denkert, H. Tesch, 2013, Breast Cancer Research.

Preanalytical variables and performance of diagnostic RNA-based gene expression analysis in breast cancer

C. Denkert, M. Dietel, H. Bojar, 2014, Virchows Archiv.

Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE).

Carsten Denkert, Stefan Michiels, Mahdi Rezai, 2017, European journal of cancer.

Quantitative Determination of Estrogen Receptor, Progesterone Receptor, and HER2 mRNA in Formalin-fixed Paraffin-embedded Tissue—A New Option for Predictive Biomarker Assessment in Breast Cancer

Carsten Denkert, Wilko Weichert, Manfred Dietel, 2011, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma

C. Denkert, H. Oettle, H. Riess, 2018, British Journal of Cancer.

Co-expression of MET and CD47 is a novel prognosticator for survival of luminal-type breast cancer patients

T. Holland-Letz, A. Schneeweiss, A. Trumpp, 2014, Oncotarget.

Metaplastic breast cancers: Genomic profiling, mutational burden and tumor-infiltrating lymphocytes.

C. Denkert, Baljit Singh, A. Troxel, 2019, Breast.

Mutational profiles of Brenner tumors show distinctive features uncoupling urothelial carcinomas and ovarian carcinoma with transitional cell histology

W. Weichert, P. Schirmacher, A. Stenzinger, 2017, Genes, chromosomes & cancer.

Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.

Tanja Fehm, Carsten Denkert, Peter A Fasching, 2012, The New England journal of medicine.

FGFR4 overexpression and hotspot mutations in metastatic ER+ breast cancer are enriched in the lobular subtype

Adrian V. Lee, C. Denkert, E. Sokol, 2019, npj Breast Cancer.

Multicentre validation study of nucleic acids extraction from FFPE tissues

S. Bonin, C. Denkert, M. Dietel, 2010, Virchows Archiv.

Remodeling of central metabolism in invasive breast cancer compared to normal breast tissue – a GC-TOFMS based metabolomics study

Oliver Fiehn, Carsten Denkert, Jan Budczies, 2012, BMC Genomics.

Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma

P. Fasching, C. Denkert, S. Loibl, 2014, Breast Cancer Research and Treatment.

Higher cytoplasmic and nuclear poly(ADP-ribose) polymerase expression in familial than in sporadic breast cancer

P. Bult, C. Denkert, M. Dietel, 2012, Virchows Archiv.

Expression of the ELAV-Like Protein HuR Is Associated with Higher Tumor Grade and Increased Cyclooxygenase-2 Expression in Human Breast Carcinoma

W. Weichert, G. Kristiansen, K. Winzer, 2004, Clinical Cancer Research.

Decentral gene expression analysis for ER+/Her2− breast cancer: results of a proficiency testing program for the EndoPredict assay

H. Höfler, P. Schirmacher, C. Denkert, 2012, Virchows Archiv.

Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium

C. Denkert, I. Vergote, S. Darb-Esfahani, 2019, Journal of Cancer Research and Clinical Oncology.

Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy.

A. Schneeweiss, C. Denkert, F. Marmé, 2016, European journal of cancer.

Vascular endothelial growth factor C mRNA expression is a prognostic factor in epithelial ovarian cancer as detected by kinetic RT-PCR in formalin-fixed paraffin-embedded tissue

W. Weichert, C. Denkert, M. Dietel, 2009, Virchows Archiv.

Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practice.

S. Loi, C. Denkert, G. Curigliano, 2017, Biochimica et biophysica acta. Reviews on cancer.

Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer – A Substudy of the Neoadjuvant GeparQuinto Trial

Carsten Denkert, Manfred Dietel, C. Denkert, 2013, PloS one.

METAtarget - Extracting Key Enzymes of Metabolic Regulation from Highthroughput Metabolomics Data using KEGG REACTION Information

Matej Oresic, Oliver Fiehn, Carsten Denkert, 2010, GCB.

Gemcitabine: results from the CONKO-001 study

B. Dörken, C. Denkert, M. Dietel, 2014 .

Does long‐term survival in patients with pancreatic cancer really exist?—Results from the CONKO‐001 study

B. Dörken, C. Denkert, H. Oettle, 2013, Journal of surgical oncology.

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006.

A. Schneeweiss, C. Denkert, A. Buzdar, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment.

B. Dörken, C. Denkert, H. Oettle, 2016, Pathology, research and practice.

Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: association with tumor progression.

C. Denkert, E. Dahl, I. Klaman, 2007, Gynecologic oncology.

High-grade ovarian serous carcinoma patients exhibit profound alterations in lipid metabolism

C. Denkert, M. Dietel, J. Budczies, 2017, Oncotarget.

Adhesion and Migration of HRT-18 Colorectal Carcinoma Cells on Extracellular Matrix Components Typical for the Desmoplastic Stroma of Colorectal Adenocarcinomas

C. Denkert, S. Hauptmann, M. Köbel, 2003, Oncology.

Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment

Edoardo Pasolli, N. Segata, C. Denkert, 2021, Cell Death & Differentiation.

Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial.

M. Rezai, P. Fasching, A. Schneeweiss, 2019, European journal of cancer.

Comparison of the RNA-based EndoPredict multigene test between core biopsies and corresponding surgical breast cancer sections

C. Denkert, M. Dietel, K. Weber, 2012, Journal of Clinical Pathology.

Expression of human Kallikrein 14 (KLK14) in breast cancer is associated with higher tumour grades and positive nodal status

M Dietel, C Denkert, W. Weichert, 2006, British Journal of Cancer.

Down-regulation of the antigen processing machinery is linked to a loss of inflammatory response in colorectal cancer.

W. Weichert, A. Stenzinger, C. Denkert, 2010, Human pathology.

Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor–Positive Breast Cancer

J. Cuzick, S. Ferree, M. Dowsett, 2018, JAMA oncology.

Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial

P. Fasching, C. Denkert, M. Dietel, 2019, Breast Cancer Research and Treatment.

Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration.

L. Esserman, C. Denkert, E. Provenzano, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group

L. Esserman, C. Denkert, E. Provenzano, 2015, Modern Pathology.

Predictive Biomarkers and Personalized Medicine Ki67Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer

P. Fasching, T. Fehm, R. Thomas, 2013 .

Ki 67 measured after neoadjuvant chemotherapy for primary breast cancer

P. Fasching, T. Fehm, C. Denkert, 2013 .

Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial.

H Tesch, S Loibl, C Denkert, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study

C. Denkert, H. Tesch, S. Loibl, 2010, Breast Cancer Research and Treatment.

Estimating the Benefits of Therapy for Early Stage Breast Cancer The St Gallen International Consensus Guidelines for the Primary Therapy of Early Breast Cancer 2019.

E. Winer, C. Denkert, M. Gnant, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Prediction of Response to Neoadjuvant Chemotherapy: New Biomarker Approaches and Concepts

C. Denkert, S. Loibl, M. Untch, 2011, Breast Care.

Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox.

H. Kuerer, C. Denkert, J. Heil, 2021, The Lancet. Oncology.

Abstract P2-08-01: Factors predicting relapse in early breast cancer patients with a pathological complete response after neoadjuvant therapy – Results of a pooled analysis based on the GBG meta-database

M. Rezai, A. Schneeweiss, C. Denkert, 2019, Poster Session Abstracts.

Signatures of mutational processes and response to neoadjuvant chemotherapy in breast cancer: A genome-based investigation in the neoadjuvant GeparSepto trial.

P. Fasching, A. Schneeweiss, C. Denkert, 2018 .

External Quality Assessment 2.0: The Importance of a Standardized Implementation of TILs for Daily and Trial Practices

J. Hartman, C. Denkert, H. Horlings, 2022, Cancers.

Recommendations for collection and handling of specimens from group breast cancer clinical trials.

M. Ellis, J. Forbes, S. Jewell, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy

C. Denkert, S. Loibl, S. Darb-Esfahani, 2011, Seminars in Immunopathology.

Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy

J. Cuzick, M. Dowsett, C. Denkert, 2016, Journal of the National Cancer Institute.

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.

P. Fasching, L. Pusztai, C. Denkert, 2022, The New England journal of medicine.

Expression of multidrug resistance‐associated protein 1 in invasive ovarian carcinoma: implication for prognosis

W. Weichert, C. Denkert, M. Dietel, 2009, Histopathology.

Resistance to chemotherapy in ovarian carcinoma.

C. Denkert, H. Lage, 2007, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.

S. Loening, G. Kristiansen, C. Denkert, 2004, Oncology reports.

Cytokeratin 5/6 expression, prognosis, and association with estrogen receptor α in high-grade serous ovarian carcinoma.

C. Denkert, M. Dietel, J. Budczies, 2017, Human pathology.

Expression, Intracellular Localization, and Prognostic Value of Plasminogen Activator Inhibitor 1 and PAI-1 RNA-Binding Protein 1 in Primary and Recurrent Ovarian Cancer: A Study of the Tumor Bank Ovarian Cancer Network

T. Kohlmann, C. Denkert, E. Dahl, 2017, Gynecologic and Obstetric Investigation.

From High-Throughput Microarray-Based Screening to Clinical Application: The Development of a Second Generation Multigene Test for Breast Cancer Prognosis

C. Denkert, Marcus Schmidt, R. Kronenwett, 2013, Microarrays.

An intracellular targeted antibody detects EGFR as an independent prognostic factor in ovarian carcinomas

W. Weichert, C. Denkert, M. Dietel, 2011, BMC Cancer.

Class IHistone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer : Specific Role of Class I Histone Deacetylases In vitro and In vivo

C. Denkert, M. Dietel, A. Noske, 2008 .

Characterization of Hormone Receptor and HER2 Status in Breast Cancer Using Mass Spectrometry Imaging

W. Weichert, K. Schwamborn, C. Denkert, 2023, International journal of molecular sciences.

Online tumor conference in the clinical management of gynecological cancer: experience from a pilot study in Germany

C Denkert, C. Denkert, D. Boehmer, 2007, International Journal of Gynecologic Cancer.

EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer

C. Denkert, A. Hasenburg, K. Almstedt, 2020, Geburtshilfe und Frauenheilkunde.

The EndoPredict Gene-Expression Assay in Clinical Practice - Performance and Impact on Clinical Decisions

K. Winzer, C. Denkert, M. Dietel, 2013, PloS one.

Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial

Sung-Bae Kim, C. Denkert, K. Gelmon, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

R. Bernards, C. Sotiriou, S. Loi, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer

C. Denkert, S. Darb-Esfahani, H. Mellstedt, 2014, Journal of gynecologic oncology.

Expression of Epithelial Cell Adhesion Molecule in Paired Tumor Samples of Patients With Primary and Recurrent Serous Ovarian Cancer

C. Denkert, S. Darb-Esfahani, H. Mellstedt, 2013, International Journal of Gynecologic Cancer.

Detection and Segmentation of Cell Nuclei in Virtual Microscopy Images: A Minimum-Model Approach

Daniel Heim, Peter Hufnagl, Carsten Denkert, 2012, Scientific Reports.

Abstract S1-09: Evaluation of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarker in different subtypes of breast cancer treated with neoadjuvant therapy - A metaanalysis of 3771 patients

A. Schneeweiss, C. Denkert, F. Klauschen, 2017 .

The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast

B. Bonanni, S. Loi, C. Denkert, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

OP-JNCI200205 808..819

M. Ellis, S. Leung, T. Nielsen, 2021 .

Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer: The REACT Randomized Clinical Trial.

C. Denkert, A. Makris, J. Bartlett, 2021, JAMA oncology.

Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer

C. Denkert, J. Budczies, S. Wienert, 2018, Neoplasia.

Expression patterns of polo‐like kinase 1 in human gastric cancer

W. Weichert, C. Denkert, M. Dietel, 2006, Cancer science.

Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma

C. Denkert, H. Oettle, H. Riess, 2018, British Journal of Cancer.

Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.

C. Denkert, M. Dietel, J. Budczies, 2013, Human pathology.

Topoisomerase IIα mRNA and protein expression in ovarian carcinoma: correlation with clinicopathological factors and prognosis

W. Weichert, C. Denkert, M. Dietel, 2009, Modern Pathology.

Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types.

L. Esserman, J. Forbes, S. Loi, 2011, The Lancet. Oncology.

Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer

Carsten Denkert, Wilko Weichert, Manfred Dietel, 2008, Cancer.

Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto‐GBG 84 Trial

P. Fasching, A. Schneeweiss, C. Denkert, 2020, Journal of the American Heart Association.

135MO HRQoL with neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522

C. Denkert, H. McArthur, S. Kuemmel, 2022, Annals of Oncology.

Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients - a study of the OVCAD consortium

G. Heinze, C. Denkert, R. Zeillinger, 2013, BMC Cancer.

Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study.

P. Fasching, W. Weichert, C. Denkert, 2019, European journal of cancer.

Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer

M. Lux, M. Beckmann, P. Fasching, 2018, Geburtshilfe und Frauenheilkunde.

Morphological and molecular breast cancer profiling through explainable machine learning

Masaru Ishii, Klaus-Robert Müller, Daniel Heim, 2021, Nature Machine Intelligence.

cancerclass: An R Package for Development and Validation of Diagnostic Tests from High-Dimensional Molecular Data

Budczies Jan, Daniel Kosztyla, Christian von Törne, 2014 .

Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer

C. Denkert, M. Dietel, J. Budczies, 2015, BMC Clinical Pathology.

Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer—results from the GeparQuattro study (GBG 40)

Carsten Denkert, Christine Solbach, K. Dietrich, 2012, Breast Cancer Research and Treatment.

Predictive Factors for Response to Neoadjuvant Therapy in Breast Cancer

C. Denkert, S. Loibl, M. Untch, 2014, Oncology Research and Treatment.

Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial

A. Schneeweiss, C. Denkert, S. Loibl, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial

M. Rezai, P. Fasching, T. Fehm, 2019, International journal of cancer.

Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial

Peter A. Fasching, Carsten Denkert, Andreas Schneeweiss, 2018, BMC Medicine.

Polo‐like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades

S. Loening, W. Weichert, G. Kristiansen, 2004, The Prostate.

P. Fasching, A. Schneeweiss, C. Denkert, 2021, Clinical Cancer Research.

Abstract PD5-08: Tumor immune-cell activity assessed by RNAseq is an independent predictor of therapy response and prognosis after neoadjuvant chemotherapy in HER2 negative breast cancer patients - An analysis of the GeparSepto trial

P. Fasching, A. Schneeweiss, C. Denkert, 2020 .

Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials.

P. Fasching, A. Schneeweiss, C. Denkert, 2020, European journal of cancer.

Abstract 4699: Responsecharacteristics and overall survival of 781 patients with triple-negativebreast cancer - a meta-analysis on 7 German neoadjuvant studies.

A. Schneeweiss, C. Denkert, S. Loibl, 2013 .

10PComparison of the mutational landscape of breast cancer during pregnancy and non-pregnant controls

W. Weichert, A. Stenzinger, C. Denkert, 2017 .

KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant therapy followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC).

J. Bergh, L. Pusztai, C. Denkert, 2018 .

A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel / carboplatin followed by epirubicin / cyclophosphamide as neoadjuvant chemotherapy in patients with HER2-negative early breast cancer and homologous recombination deficiency (HRD): GeparOLA.

P. Fasching, A. Schneeweiss, C. Denkert, 2016 .

Abstract GS3-05: Survival analysis of the prospectively randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy with weekly nab-paclitaxel with solvent-based paclitaxel followed by anthracycline/cyclophosphamide for patients with early breast cancer – GBG69

P. Fasching, A. Schneeweiss, C. Denkert, 2018 .

Reproducibility of mRNA-Based Testing of ESR1, PGR, ERBB2, and MKI67 Expression in Invasive Breast Cancer—A Europe-Wide External Quality Assessment

M. Beckmann, P. Fasching, C. Denkert, 2021, Cancers.

Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma.

C. Denkert, S. Hauptmann, M. Köbel, 2002, The American journal of pathology.

Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer

C. Sotiriou, P. Neven, S. Loi, 2015, BMC Medicine.

Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning.

K-R Müller, S Michiels, F Klauschen, 2018, Seminars in cancer biology.

Standardized Ki67 Diagnostics Using Automated Scoring—Clinical Validation in the GeparTrio Breast Cancer Study

Carsten Denkert, Stephan Wienert, Frederick Klauschen, 2014, Clinical Cancer Research.

Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane–Anthracycline Containing Chemotherapy—DAFNE (GBG-70)

A. Schneeweiss, C. Denkert, S. Loibl, 2015, Clinical Cancer Research.

Quantitative determination of predictive cancer biomarkers in formalin-fixed, paraffin-embedded tissue using a new, fully automated method for RNA isolation.

G. Kristiansen, K. Winzer, C. Denkert, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quantitative analysis of diagnostic guidelines for HER2-status assessment.

A. Warth, W. Weichert, A. Stenzinger, 2012, The Journal of molecular diagnostics : JMD.

Impact of Nuclear Oestrogen Receptor Beta Expression in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

C. Denkert, S. Loibl, J. Blohmer, 2019, Geburtshilfe und Frauenheilkunde.

Outcome after neoadjuvant chemotherapy in elderly breast cancer patients – a pooled analysis of individual patient data from eight prospectively randomized controlled trials

P. Fasching, A. Schneeweiss, C. Denkert, 2018, Geburtshilfe und Frauenheilkunde.

Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials

A. Schneeweiss, C. Denkert, S. Loibl, 2015, Breast Cancer Research and Treatment.

Neutrophil Gelatinase-Associated Lipocalin (NGAL) Predicts Response to Neoadjuvant Chemotherapy and Clinical Outcome in Primary Human Breast Cancer

C. Denkert, W. Jonat, S. Loibl, 2012, PloS one.

Validated 3 Gene Signature Predicts Response to Neo-Adjuvant Chemotherapy in Luminal Breast Cancer – Results from GeparTrio and GeparQuattro.

C. Denkert, J. Budczies, S. Loibl, 2009 .

Local versus central HER2 immunohistochemistry correlates with kinetic RT-PCR but only central immunohistochemistry and RT-PCR predict pathological complete response: results from the neoadjuvant multicenter GeparTrio trial.

C. Denkert, S. Loibl, R. Wirtz, 2009 .

An inhibitor of stress-activated MAP-kinases reduces invasion and MMP-2 expression of malignant melanoma cells

C. Denkert, S. Hauptmann, A. Siegert, 2004, Clinical & Experimental Metastasis.

Interferon-stimulated Gene, 15 kDa (ISG15) in Ovarian High-grade Serous Carcinoma: Prognostic Impact and Link to NF-&kgr;B Pathway

C. Denkert, M. Dietel, S. Darb-Esfahani, 2014, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

Low Expression of RGS2 Promotes Poor Prognosis in High-Grade Serous Ovarian Cancer

C. Denkert, W. Schmitt, J. Sehouli, 2022, Cancers.

The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

Andrew H. Beck, Clare C. Yu, M. N. Vidya, 2021, npj Breast Cancer.

Tumor-Infiltrating Lymphocytes: A Promising Biomarker in Breast Cancer

C. Denkert, S. Loibl, B. Ingold Heppner, 2016, Breast Care.

Prognostic impact of neuroendocrine differentiation in high-grade serous ovarian carcinoma

C. Denkert, M. Dietel, S. Darb-Esfahani, 2015, Virchows Archiv.

DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status

P. Fasching, C. Denkert, F. Klauschen, 2021, Clinical Epigenetics.

DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status

P. Fasching, C. Denkert, F. Klauschen, 2021, Clinical epigenetics.

Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial

P. Fasching, C. Denkert, F. Marmé, 2019, British Journal of Cancer.

Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials.

M. Rezai, P. Fasching, A. Schneeweiss, 2021, European journal of cancer.

Prognostic impact of AMP-activated protein kinase expression in ovarian carcinoma: correlation of protein expression and GC/TOF-MS-based metabolomics.

O. Fiehn, W. Weichert, C. Denkert, 2011, Oncology reports.

Loss of Gelsolin expression in human ovarian carcinomas.

W. Weichert, C. Denkert, M. Dietel, 2005, European journal of cancer.

NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in Patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo.

C. Denkert, J. Costantino, C. Geyer, 2018 .

Borderline tumors of the ovary and peritoneal implants.

C. Denkert, M. Dietel, 2005, Verhandlungen der Deutschen Gesellschaft fur Pathologie.

Expression of the ELAV-like protein HuR in human prostate carcinoma is an indicator of disease relapse and linked to COX-2 expression.

W. Weichert, G. Kristiansen, C. Denkert, 2008, International journal of oncology.

Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

S. Mallal, R. Yelensky, S. Loi, 2019, Clinical Cancer Research.

Predictive value of sphingosine kinase 1 expression in neoadjuvant treatment of breast cancer

C. Denkert, S. Loibl, V. Nekljudova, 2013, Journal of Cancer Research and Clinical Oncology.

KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)

P. Fasching, L. Pusztai, C. Denkert, 2019, Annals of Oncology.

Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response.

C. Denkert, V. Nekljudova, J. Blohmer, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-term survival of breast cancer patients with brain metastases: subanalysis of the BMBC registry

T. Fehm, C. Denkert, V. Nekljudova, 2022, ESMO open.

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer - clinical results and biomarker analysis of GeparNuevo study.

K. Weber, M. Rezai, P. Fasching, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy

P. Fasching, C. Denkert, B. Seliger, 2019, Breast Cancer Research.

Introduction on Genome-wide Expression Profiling from Formalin-Fixed Paraffin-Embedded Tissues Using Microarrays

W. Weichert, C. Denkert, M. Dietel, 2011 .

[Update of the German S3 breast cancer guideline : What is new for pathologists?]

C. Denkert, A. Lebeau, P. Sinn, 2019, Der Pathologe.

Strategies for developing Ki67 as a useful biomarker in breast cancer.

Carsten Denkert, Jan Budczies, Stephan Wienert, 2015, Breast.

Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer

R. Gray, C. Sotiriou, S. Loi, 2022, NPJ breast cancer.

APOBEC 3 B protein expression and mRNA analyses in patients with 1 high-grade serous ovarian carcinoma 2

C. Denkert, M. Dietel, J. Sehouli, 2018 .

Prognostic Relevance of AGR2 Expression in Breast Cancer

G. Kristiansen, K. Winzer, E. Mayordomo, 2006, Clinical Cancer Research.

Clinical Decision Making in Chronic Myeloid Leukemia Based on Polymerase Chain Reaction Analysis of Minimal Residual Disease

C. Denkert, K. Possinger, W. Sterry, 2017 .

Tumor-In fi ltrating Lymphocytes and Prognosis : A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers

R. Gray, C. Sotiriou, S. Loi, 2019 .

SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study.

M Dietel, C Denkert, B. Dörken, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Monounsaturated fatty acids in serum triacylglycerols are associated with response to neoadjuvant chemotherapy in breast cancer patients

Carsten Denkert, Tuulia Hyötyläinen, Matej Orešič, 2014, International journal of cancer.

Phase III postneoadjuvant study evaluating sacituzumab govitecan, an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA.

C. Denkert, F. Marmé, S. Loibl, 2021 .

Reproducibility and concordance of 4 clinically developed programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) assays in triple-negative breast cancer (TNBC)

W. Weichert, C. Denkert, A. Noske, 2019, Geburtshilfe und Frauenheilkunde.

Ambivalent role of pFAK-Y397 in serous ovarian cancer-a study of the OVCAD consortium

C. Denkert, R. Zeillinger, I. Vergote, 2014, Molecular Cancer.

KRAS Mutations in Codon 12 or 13 Are Associated With Worse Prognosis in Pancreatic Ductal Adenocarcinoma

W. Weichert, A. Stenzinger, C. Denkert, 2014, Pancreas.

Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor

C. Denkert, F. Marmé, S. Loibl, 2018, Clinical Cancer Research.

Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab (P) in HER2+ breast cancer (BC): Biomarker analysis of the APHINITY trial.

S. Loi, M. Piccart, C. Denkert, 2019, Journal of Clinical Oncology.

Correction to: De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (Annals of Oncology (2017) 28(8) (1700–1712), (S0923753419321817), (10.1093/annonc/mdx308))

E. Winer, J. Cuzick, J. Bergh, 2017 .

Overexpression of cyclooxygenase‐2 in human prostate carcinoma and prostatic intraepithelial neoplasia‐association with increased expression of polo‐like kinase‐1

W. Weichert, G. Kristiansen, C. Denkert, 2007, The Prostate.

Low TMB as predictor for additional benefit from neoadjuvant immune checkpoint inhibition in triple-negative breast cancer.

A. Schneeweiss, C. Denkert, S. Loibl, 2022, Journal of Clinical Oncology.

Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC).

P. Fasching, A. Schneeweiss, C. Denkert, 2021, Journal of Clinical Oncology.

168MO GeparX: Denosumab (Dmab) as add-on to different regimen of nab-paclitaxel (nP)-anthracycline based neoadjuvant chemotherapy (NACT) in early breast cancer (BC): Subgroup analyses by RANK expression and HR status

A. Schneeweiss, C. Denkert, S. Loibl, 2020 .

Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group.

Sarah N. Dudgeon, A. Beck, T. Nielsen, 2020, NPJ breast cancer.

Initial Treatment of Patients with Primary Breast Cancer : Evidence , Controversies , Consensus Spectrum of Opinion of German Specialists at the 15 th International

P. Fasching, T. Fehm, A. Schneeweiss, 2017 .

MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial

P. Fasching, C. Denkert, F. Heppner, 2020, PloS one.

Characteristics of patients with brain metastases from human epidermal growth factor receptor 2-positive breast cancer: subanalysis of Brain Metastases in Breast Cancer Registry

T. Fehm, C. Denkert, V. Nekljudova, 2022, ESMO open.

Pathological Workup of Surgical Breast Cancer Specimens after Neoadjuvant Chemotherapy

C. Denkert, 2006, Breast Care.

Abstract P3-07-55: Predictive value of O6-methylguanine-DNA methyltransferase (MGMT) promoter gene methylation in triple-negative breast cancer patients receiving carboplatin

P. Fasching, A. Schneeweiss, C. Denkert, 2016 .

CD 24 Expression Is a New Prognostic Marker in Breast Cancer

C. Pilarsky, G. Kristiansen, K. Winzer, 2003 .

Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy

P. Fasching, C. Denkert, B. Seliger, 2019, Breast Cancer Research.

Endoscopic ultrasound-fine needle biopsies of pancreatic lesions: Prospective study of histology quality using Franseen needle

C. Denkert, T. Gress, L. Breitling, 2020, World journal of gastroenterology.

Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group

J. Hartman, P. V. van Diest, C. Denkert, 2021, Cancers.

Ioncopy: a novel method for calling copy number alterations in amplicon sequencing data including significance assessment

Carsten Denkert, Jan Budczies, Nicole Pfarr, 2016, Oncotarget.

High expression of RelA/p65 is associated with activation of nuclear factor-κB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis

W. Weichert, G. Kristiansen, C. Denkert, 2007, British Journal of Cancer.

Abstract GS3-03: A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients (REACT – Randomised EuropeAn celecoxib trial)

M. Rezai, C. Denkert, A. Makris, 2018 .

Abstract S5-05: Postneoadjuvant treatment with zoledronate in patients with tumor residuals after anthracyclines-taxane-based chemotherapy for primary breast cancer – The phase III NATAN study (GBG 36/ABCSG XX)

M. Rezai, P. Fasching, A. Schneeweiss, 2013 .

Anterior gradient protein 2 (AGR2) is an independent prognostic factor in ovarian high-grade serous carcinoma

W. Weichert, G. Kristiansen, C. Denkert, 2012, Virchows Archiv.

A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer

C. Sotiriou, C. Desmedt, C. Denkert, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

How Much Information Do We Really Need After Neoadjuvant Therapy for Breast Cancer?

C. Denkert, S. Loibl, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interleukin-10 in serous ovarian carcinoma cell lines

C. Denkert, S. Hauptmann, M. Köbel, 2001, Cancer Immunology and Immunotherapy.

160O Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer, TNBC) (PM(Cb)) for patients (pts) with high-risk early breast cancer (BC)

A. Schneeweiss, C. Denkert, H. Tesch, 2020 .

mdm2 gene amplification is associated with luminal breast cancer progression in humanized PDX mice and a worse outcome of estrogen receptor positive disease

A. Trumpp, C. Denkert, S. Loibl, 2021, International journal of cancer.

Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial

P. Fasching, C. Denkert, F. Marmé, 2019, British Journal of Cancer.

KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptor–positive, human epidermal growth factor receptor 2–negative (ER+/HER2−) breast cancer.

S. Loi, C. Denkert, D. Cescon, 2019, Journal of Clinical Oncology.

Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness

C. Denkert, W. Symmans, H. Rugo, 2021, npj Breast Cancer.

Abstract GS1-01: KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses

P. Fasching, L. Pusztai, C. Denkert, 2022, Cancer Research.

Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium

C. Denkert, D. Tong, R. Zeillinger, 2012, Molecular Cancer.

Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial.

C. Denkert, M. Watson, W. Symmans, 2021, JAMA oncology.

New network topology approaches reveal differential correlation patterns in breast cancer

Carsten Denkert, Jan Budczies, Frederick Klauschen, 2013, BMC Systems Biology.

Value of preoperative transvaginal sonography (TVS) in the description of tumor pattern in ovarian cancer patients: results of a prospective study.

C. Denkert, W. Henrich, C. Wolf, 2007, Anticancer research.

Germline mutation status and therapy response in high-risk early breast cancer: Results of the GeparOcto study (NCT02125344).

P. Fasching, A. Schneeweiss, C. Denkert, 2019, Journal of Clinical Oncology.

Exome analysis of oncogenic pathways and tumor mutational burden (TMB) in triple-negative breast cancer (TNBC): Results of the translational biomarker program of the neoadjuvant double-blind placebo controlled GeparNuevo trial.

P. Fasching, A. Schneeweiss, C. Denkert, 2019, Journal of Clinical Oncology.

60MO Ovarian function in young patients (pts) treated with postneoadjuvant palbociclib (PAL) and endocrine therapy (ET) for hormone receptor (HR)-positive, HER2-negative early breast cancer (BC): Explorative analysis in Penelope-B

C. Denkert, F. Marmé, V. Nekljudova, 2022, Annals of Oncology.

MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer

C. Denkert, A. Lánczky, Zsófia Pénzváltó, 2014, BMC Cancer.

Morphomolecular analysis of the immune tumor microenvironment in human head and neck cancer

W. Weichert, P. Schirmacher, A. Stenzinger, 2019, Cancer Immunology, Immunotherapy.

Prognostic value of regulatory T cells and T helper 17 cells in high grade serous ovarian carcinoma

C. Denkert, W. Schmitt, J. Sehouli, 2022, Journal of Cancer Research and Clinical Oncology.

Expression of lysophosphatidic acid acyltransferase beta (LPAAT-β) in ovarian carcinoma: correlation with tumour grading and prognosis

W. Weichert, C. Denkert, M. Dietel, 2005, British Journal of Cancer.

Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test

C. Denkert, M. Dietel, K. Weber, 2012, BMC Cancer.

Gene Expression Analyses in Early Breast Carcinoma — Quo Vadis? Genexpressionsanalysen beim frühen Mammakarzinom – quo vadis?

C. Denkert, Marcus Schmidt, K. Almstedt, 2017, Senologie - Zeitschrift für Mammadiagnostik und -therapie.

Acute myocardial infarction caused by coronary tumor thromboembolism: a rare primary manifestation of malignant tumor disease.

W. Weichert, C. Denkert, M. Dietel, 2006, Human Pathology.

Breast cancer, locally advanced and metastatic

L. Holmberg, O. Nanni, S. Barni, 2012 .

Klinisch relevante molekularpathologische Diagnostik beim Mammakarzinom

C. Denkert, P. Jank, A. Lebeau, 2023, Die Pathologie.

Effect of mast cells on efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme b.

P. Fasching, T. Fehm, C. Denkert, 2017 .

TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer

P. Fasching, C. Denkert, F. Marmé, 2021, BMC Cancer.

TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer

P. Fasching, C. Denkert, F. Marmé, 2021, BMC cancer.

Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522.

P. Fasching, J. Bergh, L. Pusztai, 2022, Journal of Clinical Oncology.

GeparDouze/NSABP B-59: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo in patients with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo.

C. Denkert, S. Loibl, V. Nekljudova, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract S1-05: Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC)

C. Sotiriou, S. Loi, C. Desmedt, 2013 .

Immunological Mechanisms in Breast Cancer - from Bench to Bedside

C. Denkert, F. Schütz, 2016, Breast Care.

Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE).

P. Fasching, A. Schneeweiss, C. Denkert, 2017, European journal of cancer.

Abstract P5-16-03: Peripheral sensory neuropathy occurrence and resolution: Results from the neoadjuvant randomized GeparSepto study (GBG 69)

A. Schneeweiss, C. Denkert, S. Loibl, 2017 .

1O KEYNOTE-522 Asian subgroup: Phase III study of neoadjuvant pembrolizumab (pembro) vs placebo (pbo) + chemotherapy (chemo) followed by adjuvant pembro vs pbo for early triple-negative breast cancer (TNBC)

P. Fasching, L. Pusztai, C. Denkert, 2020 .

Klinisch relevante molekularpathologische Diagnostik beim Mammakarzinom

C. Denkert, P. Jank, A. Lebeau, 2023, Wiener klinisches Magazin.

T E C H N I C a L a D V a N C E Open Access

C. Denkert, M. Dietel, K. Weber, 2022 .

Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study

C. Denkert, H. Oettle, H. Riess, 2021, Frontiers in Oncology.

Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivo

W. Weichert, C. Denkert, M. Dietel, 2008, Clinical Cancer Research.

Recommendations for collection and handling of specimens from group breast cancer clinical trials.

M. Ellis, J. Forbes, S. Jewell, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Monounsaturated fatty acids in serum triacylglycerols are associated with response to neoadjuvant chemotherapy in breast cancer patients

C. Denkert, M. Orešič, S. Loibl, 2014, International journal of cancer.

Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer - overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression

Carsten Denkert, Jan Budczies, Wilko Weichert, 2013, BMC Cancer.

C. Sotiriou, S. Loi, C. Denkert, 2015, JAMA oncology.

Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.

C. Sotiriou, S. Loi, C. Denkert, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types.

L. Esserman, J. Forbes, S. Loi, 2011, The Lancet. Oncology.

Standardized Ki67 Diagnostics Using Automated Scoring—Clinical Validation in the GeparTrio Breast Cancer Study

C. Denkert, M. Dietel, S. Wienert, 2014, Clinical Cancer Research.

Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer

P. Fasching, T. Fehm, C. Denkert, 2013, Clinical Cancer Research.

The landscape of metastatic progression patterns across major human cancers

A. Warth, W. Weichert, A. Stenzinger, 2014, Oncotarget.

Estrogen receptor 1 mRNA is a prognostic factor in ovarian carcinoma: determination by kinetic PCR in formalin-fixed paraffin-embedded tissue.

W. Weichert, C. Denkert, M. Dietel, 2009, Endocrine-related cancer.

Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) – Recommendations for Daily Routine Practice

P. Fasching, A. Schneeweiss, C. Denkert, 2019, Geburtshilfe und Frauenheilkunde.

Differential expression of secretoglobins in normal ovary and in ovarian carcinoma--overexpression of mammaglobin-1 is linked to tumor progression.

C. Denkert, C. Ufer, H. Kuhn, 2014, Archives of biochemistry and biophysics.

IMP3 Expression in Human Ovarian Cancer is Associated With Improved Survival

W. Weichert, C. Denkert, M. Dietel, 2009, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours.

W. Weichert, A. Stenzinger, C. Denkert, 2011, Endocrine-related cancer.

P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment.

B. Dörken, C. Denkert, H. Oettle, 2016, Pathology, research and practice.

Flat epithelial atypia is a common subtype of B3 breast lesions and is associated with noninvasive cancer but not with invasive cancer in final excision histology.

W. Weichert, C. Denkert, M. Dietel, 2010, Human pathology.

Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2).

A. Schneeweiss, C. Denkert, F. Marmé, 2021, European journal of cancer.

[Imatinib--a possible therapeutic option for cervical carcinoma: results of a preclinical phase I study].

C. Denkert, R. Kimmig, J. Blohmer, 2008, Gynakologisch-geburtshilfliche Rundschau.

Ioncopy: a novel method for calling copy number alterations in amplicon sequencing data including significance assessment

W. Weichert, A. Stenzinger, C. Denkert, 2016, Oncotarget.